SCHEMBL3107181

SCHEMBL3107181

CCc1sc(C2=CCSCC2)cc1C(Cl)C1CCCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3101557 0.73 IDO1 (0.32)
SCHEMBL3110369 0.72 IDO1 (0.34)
SCHEMBL3261048 0.70 MEN1 (0.33)
SCHEMBL3102210 0.70 KCNH2 (0.33)
SCHEMBL3111456 0.70 IDO1 (0.33)
SCHEMBL3090137 0.70 GCGR (0.43)
SCHEMBL3102869 0.69 SMN1; SMN2 (0.33)
SCHEMBL3106944 0.68 IDO1 (0.32)
SCHEMBL3107032 0.68 IDO1 (0.32)
SCHEMBL3111425 0.59 ALDH1A1 (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2210876-B1 HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST TAKEDA PHARMACEUTICAL (JP) 2015-05-20 EP disclosed
US-8309580-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-13 US disclosed
US-20100256156-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-07 US disclosed
EP-2210876-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-07-28 EP disclosed